Figure 2: Examples from more than 30 bioassays developed as both potency and neutralizing antibody (NAb) assays for biosimilars; (a) response to three commercial insulin therapeutics (Humalog, Novolog, and Lantus) in a cell-based functional assay that measure activation of human insulin receptor; (b) a GLP1 and Exendin-4 bioassay was developed to accelerate development of biosimilars to metabolic drugs using a cyclic AMP readout in live cells. (c) A bioassay developed for anti-TNFα drugs enables users to benchmark drugs such as adalimumab, infliximab, etanercept, golimumab, and certolizumab against their respective biosimilar molecules. (d) A simple assay determines potency of the antiinflammatory antibody Ustekinumab.
{}